Hepatocellular carcinoma staging systems: Hong Kong liver cancer vs Barcelona clinic liver cancer in a Western population

Table 1 Concordance in the treatment of hepatocellular carcinoma proposed by the Hong Kong liver cancer system and Barcelona clinic liver cancer classification

	BCLC-0	BCLC-A	BCLC-B	BCLC-C	BCLC-D
	(ablation, LR or LT)	(ablation, LR or LT)	(TACE)	(SOR)	(ST)
HKLC-I (ablation, LR or LT)	√	√
HKLC-IIA (ablation, LR or LT)	√	√
HKLC-IIB (LR)	√	√
HKLC-IIIA (TACE)			√
HKLC-IIIB (TACE)			√
HKLC-IVA (SOR)				√
HKLC-IVB (SOR or ST)				√
HKLC-VA (LT)
HKLC-VB (ST)					√

The tick in the table means that there was agreement in the treatment of HCC proposed by the HKLC system and BCLC classification. BCLC: Barcelona clinic liver cancer; HCC: Hepatocellular carcinoma; HKLC: Hong Kong liver cancer; LR: Liver resection; LT: Liver transplantation; ST: Symptomatic treatment; SOR: Sorafenib; TACE: Transarterial chemoembolization.

Table 2 General data of patients with hepatocellular carcinoma

Variables1	HCC (n = 519)
Race
White	462 (89.0)
Black	35 (6.8)
Others	22 (4.2)
Etiology
HCV	407 (78.4)
Alcohol abuse	194 (37.4)
HBV	31 (6.0)
NAFLD	23 (4.4)
Cryptogenic cirrhosis	9 (1.7)
Alpha-fetoprotein (ng/mL)
< 400	361 (69.6)
≥ 400	109 (21.0)
Data not available	49 (9.4)
Child-Pugh score
A	273 (52.6)
B	181 (34.9)
C	65 (12.5)
Multifocal Tumor
Yes	261 (50.3)
No	258 (49.7)
Tumor size, cm
< 10 cm	449 (86.5)
≥ 10 cm	30 (5.8)
Data not available	40 (7.7)

¹Variables described by frequency (%). HCC: Hepatocellular carcinoma; NAFLD: Non-alcoholic fatty liver disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus.

Table 3 Concordance in the treatment of hepatocellular carcinoma proposed by the Hong Kong liver cancer system and Barcelona clinic liver cancer classification in a South American population

Variables1	BCLC-0 (ablation, LR or LT)	BCLC-A (ablation, LR or LT)	BCLC-B (TACE)	BCLC-C (SOR)	BCLC-D (ST)
HKLC-I (ablation, LR or LT)	25 (100%)	129 (52.4%)	24 (22.4%)
HKLC-IIA (ablation, LR or LT)		84 (34.1%)	11 (10.3%)
HKLC-IIB (LR)		25 (10.2%)	22 (20.6%)
HKLC-IIIA (TACE)		8 (3.3%)	20 (18.7%)	1 (1.3%)
HKLC-IIIB (TACE)			30 (28.0%)
HKLC-IVA (SOR)				32 (42.1%)
HKLC-IVB (SOR or ST)				43 (56.6%)
HKLC-VA (LT)					38 (58.5%)
HKLC-VB (ST)					27 (41.5%)

¹Variables described by frequency (%). The highlighted square in the table means that there was agreement in the treatment of HCC proposed by the HKLC system and BCLC classification. BCLC: Barcelona clinic liver cancer; HCC: Hepatocellular carcinoma; HKLC: Hong Kong liver cancer; LR: Liver resection; LT: Liver transplantation; ST: Symptomatic treatment; SOR: Sorafenib; TACE: Transarterial chemoembolization.